New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
09:06 EDTELGXEndologix announces revenue milestone for Nellix EndoVascular System
Endologix announced that it has achieved $10M in trailing twelve month international sales of the Nellix EndoVascular Aneurysm Sealing System, triggering a milestone payment to the former Nellix stockholders, in the form of 2,666,555 shares of Endologix common stock. Based on the company's 2010 acquisition agreement for Nellix, the revenue milestone triggered a $20M payment in Endologix common stock to former Nellix stockholders. The stock price used to calculate the share payment is subject to a floor of $3.50 and a ceiling of $7.50. Accordingly, because Endologix's stock price is currently above the $7.50 ceiling, the company will issue 2,666,555 shares by the end of June. Nellix has obtained CE Mark and is currently undergoing a U.S. Investigational Device Exemption trial to establish clinical evidence for U.S. Food and Drug Administration approval. The U.S. study, EVAS FORWARD-IDE is approved to enroll 180 patients at up to 30 sites in the U.S., Canada and Europe. The EVAS FORWARD Global Registry is planned to include 300 patients enrolled in up to 30 international centers. Nellix has not been approved for marketing or commercial sale in the U.S.
News For ELGX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2015
08:45 EDTELGXEndologix to present 'positive' Nellix clinical data at VEITH Symposium
Subscribe for More Information
07:32 EDTELGXCanaccord to hold a forum
Subscribe for More Information
November 18, 2015
16:04 EDTELGXEndologix, TriVascular announce early termination of HSR waiting period
Subscribe for More Information
10:01 EDTELGXEndologix to host investor meeting
Investor meeting to be held in New York on November 19 at 6 pm. Webcast Link
07:41 EDTELGXEndologix announces start of physician-initiated registry of Nellix EVAS System
Endologix announced the start of a physician-initiated registry of the Nellix EndoVascular Aneurysm Sealing System, or Nellix EVAS System, used with aortic branch stent grafts for the treatment of patients with complex abdominal aortic aneurysms, or AAAs. The registry, to be conducted outside of the United States, will be called the ASCEND Registry. The primary investigators are Andrew Holden, MD, Associate Professor of Radiology at Auckland Hospital; and Professor Matthew Thompson, MD, Professor of Vascular Surgery, St. Georges Vascular Institute, London. The Nellix System received CE Mark in 2013 for the treatment of patients with infrarenal AAAs. The Nellix System is an investigational device in the United States.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use